To provide oncology, managed care and specialty pharmacists with advanced knowledge of how to optimally manage patients with myelofibrosis, such that they can identify and recommend appropriate patient-specific treatments that are cost-effective, develop optimal toxicity prevention and management, and to improve patient outcomes.
Upon completion of this program, participants should be better able to:
-Discuss the pathophysiology of myelofibrosis
-Examine current treatment options and emerging therapies for myelofibrosis
-Demonstrate effective approaches to prevent and manage adverse effects of therapies used to treat myelofibrosis
-Formulate strategies to determine appropriate recommendations for formulary management, drug-tier assignments and prior authorizations
This accredited activity has been designed for oncology, managed care, and specialty pharmacist.